Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
In addition to being a lawyer with a specific interest in securities and compliance law, Omnivestor has been an avid investor for the past ten years, specializing in small cap stocks undergoing special situations. Omnivestor is also currently part of the management team at a small boutique equity research firm.
Omnivestor lives on the East coast.
Disclosure : I am not a stockbroker or financial adviser. I am an investor making researched observations for the purpose of discussion and open communication and analysis of companies and stocks. All articles are my opinion only and are not suggestions to buy or sell any equity, bond, option or other financial instrument.
I have a diverse background—as a financial journalist, resident physician, mixed martial artist, painter, entrepreneur, chemistry instructor and web developer—that enabled me to pioneer the “Integrated Investing Research” approach.
I provide consulting to clients, both the retail and professional investors. I accurately forecasted many clinical trials, such as the Flint Trials for Intercept, the Ascend Trials for InterMune and the Affinity Trials MannKind, just to name a few. Through Vincata Enterprises, LLC, I helped many clients to unlock substantial values for their investments.
As an expert in biopharmaceutical analysis, I am also more than capable of analyzing any other industries. Though not shown on Seeking Alpha, I have picked an aggregate basket of outperforming stocks.
Investing in biotech is highly risky, but it can be quite rewarding when investors have an edge in data analysis. Physicians who are rigidly scientific tend to lack the analytical prowess of financial experts. Conversely, financiers usually do not possess a physician’s medical expertise. Likewise, scientists are skillful in data analysis; yet they might not be familiar with a physician’s prescribing patterns, which is a requisite to successful biotech investing.
You can visit my website at https://www.retailinvestor360.com for business inquiry.
Mr. Cyna is an accomplished investor in the Canadian public markets for over 20 years, and has managed significant portfolios. He is a financing specialist for private and public companies, and has expertise in real estate and debt obligations. He has assisted private companies accessing the public markets, has been a founding director of public companies and is a strategic consultant to selected clientele.
He is and has been a director, a senior officer and on the Advisory Board of a number of TSX and TSXV public companies in the mining, resource, technology and telecommunications sectors, and the Founding Director of two CPC’s with qualifying transactions in mining and minerals. He was an honorary director of the Rotman School of Management MBA IMC program, has completed the Canadian Securities Institute Canadian Securities Course & Institute Conduct and Practices Handbook Course, was a former Manager under contract to an Investment Manager at BMO Nesbitt Burns, a roster mediator under the Ontario Mandatory Mediation Program, Toronto, a member of the Institute of Corporate Directors of Ontario, a member of the Upper Canada Dispute Resolution Group, and the Ontario Bar Association, Alternate Dispute Resolution section.
He obtained his designation as a Chartered Accountant in Ontario in 1971 and was the recipient of the Founder’s Prize for academic achievement together with a cash reward. He became a CPA in the State of Illinois, USA in 1999 under IQEX with a grade of 92%. He is a Member of the Institute of Chartered Accountants of Ontario and the Canadian Institute of Chartered Accountants.
He holds certificates in Advanced ADR & in Civil Justice in Ontario, Faculty of Law, University of Windsor, certificate in Dispute Resolution from the Ontario Institute of Chartered Accountants. Previous accomplishments are Manager of Cymor Risk Consultants LP specializing in Risk Management Assessment; CEO of Cyna & Associates specializing in mediation and ADR; Founder & Senior Partner of Cyna & Co, Chartered Accountants, a fully licensed and accredited public accountancy firm with international affiliations; and was a partner in a large public accountancy firm.
Mr. Cyna is well known in the Canadian Investing community. He attends presentations given by public companies to the industry on a daily basis.. These presentations are intended by the various hosting companies to present their inside story for the purpose of attracting funding, or of making parties more interested in acquiring shares of those companies. Being in constant communication in this manner keeps Mr. Cyna deeply involved in the current market and leads to numerous investment opportunities.
Mr. Cyna is currently a Director of Argentum Silver Corporation and Telehop Communications Inc.
Roger Nusbaum is the ETF Strategist for AdvisorShares. This Arizona-based professional has over 25 years of industry experience. He is also a well-known financial commentator covering ETFs, retirement planning and portfolio management for AlphaBaskets.com and at TheStreet.com. We think Roger is particularly insightful on exchange-traded funds, risk management and investing in international markets.
Visit Roger's work at Random Roger (http://randomroger.blogspot.com) and AlphaBaskets (http://alphabaskets.com)
EP Vantage is a forward-looking comment and analysis service tailored to the needs of pharma and finance professionals, focusing on the events that will define the future of companies, products and therapy areas. Written by experienced journalists, EP Vantage provides timely financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A, giving fresh angles and insight to both current and future industry triggers. EP Vantage is powered by EvaluatePharma, the industry leader in consensus forecasts.
I've made the decision to no longer contribute content on this platform. I've done so due to irreconcilable differences of opinion with the editors of Seeking Alpha regarding what I believe to be inconsistent, absent and deeply biased editorial oversight. Favoritism is the motive that moves these decisions and is granted not on the basis of merit, but on thematic considerations (short-position articles are given massive leeway) and on pragmatic considerations (who can make Seeking Alpha the most money). For readers, this creates a problematic environment where a marketplace of competing ideas is crushed in favor of compliance to preconceived and sterile thinking. Participation in "The Marketplace" is coerced in order for one's contributions to be labelled "premium" even if that content is far from the meaning that the word "premium" implies. Additionally, certain contributors are allowed to play by their own rules and in so doing the well being of all investors is compromised. While I applaud the idea of moving the markets through well researched and articulated ideation, I deplore manipulation of the market through false pretense and deliberate, unethical and morally repugnant activities. When I have brought my concerns to the editors, I've been told unequivocally that these matters don't concern them or, alternatively, that they do not wish to play the role of regulators. In both instances, I find these responses unacceptable if only because the core idea of Seeking Alpha as the democratization of the stock market through the publication of buy-side analysis is so worth protecting. I leave you, my readers, with a deep sense of gratitude for all the encouragement you've given me. In my absence, I ask only that you do your own due diligence and recognize that the opinions of bloggers, such as myself, are not to be acted upon. No opinion expressed by any contributor, most especially myself, constitutes an offer or suggestion to buy, sell, or hold any security. Always consult an investment professional before making any investment decision. In the absence of professional guidance, learn all that you can about one particular sector of investment. Follow the development of not only the companies involved, but the science, technology and persons associated with the business sector you've chosen. Remember your successes and learn from your mistakes.
Always be well...
P.S. Scrying Biotech is not, and has never been a pseudonym. It's just the coolest logo in biotech blogging. My name is, Michael Webb. And I live in the greatest city on earth - Seattle, Washington.
Started investing in the stock market in 1995.
Very slow learning process but was eager to learn about economics and general investing.
Survived the dot com implosion, the housing bubble(thankx Greenspan / Bernanke) and am still standing after the 2007 implosion!
I am very committed to the theory that we are no longer operating in a "Free Market System", ever since the fed became committed to propping up risk assets and not allowing the system to clear.
If Greenspan had allowed the system to "Reset", Clear in 2000, we would be closer to coming out the other side today.
The interventions of Greenspan first and Bernanke today force us to try and survive in a deflationary morass of the Fed's making!
I am an optimist, I am a God loving American who at almost 50 years old has seen the best and worst of our country. I pray we return to the grace of the founding fathers vision for our republic, to the "Law's of God", that has served us so well for over 200 years.
We are a republic, founded on "Equal Justice" not the perversion of "Social Justice" as pushed by this current president.
We will overcome, America is great because Americans are good!
God bless this great country.
After completing both a PhD in physiology and an MBA, I am interested in leveraging both areas of expertise to provide in depth analysis of the biotech sector. I began analyzing and covering biotech stocks in 2006. My interest in this sector is a result of my past experience in this industry which ranges from R&D to strategic management at several large and small biotech firms. With a broad scientific background and formal training in finance, I seek to leverage my knowledge and industry experience to provide a deep understanding of the markets and science that drive value in microcap healthcare stocks.
The material presented in these reports is provided for information purposes only and is not to be used or considered as a recommendation to buy, hold or sell any securities or other financial instruments. Information contained herein has been compiled and prepared from various public and industry sources that I believe to be reliable; however, no representation or warranty is expressed or implied as to the accuracy or completeness of the information. Such information is provided with the expectation that it will be read as part of a broader analysis and should not be relied upon on a stand-alone basis. Past performance should not be taken as an indication or guarantee of future performance, and I make no representation or warranty regarding future performance. The opinions expressed in this report reflect my judgment as of the date of this report and are subject to change without notice. These reports are not an offer to sell or a solicitation of an offer to buy any securities. The offer and sale of securities are regulated generally in various jurisdictions, particularly the manner in which securities may be offered and sold to residents of a particular country or jurisdiction. Securities discussed in these reports may not be eligible for sale in some jurisdictions. To the full extent provided by law neither myself nor any other person accepts any liability whatsoever for any direct or consequential loss arising from any use of this report or the information contained herein. I am not on the Board of Directors of a covered company. I do not invest in the securities of the company that is the subject of these reports unless otherwise indicated. I have not been compensated by the company that is the subject of these reports.
Turn-around CEO with successful strategy and executive-team-performance-improvement consulting business.
Semi-retired (not working full time but serve on 2 corporate Boards) and re-balancing my portfolio to dividend growth. Objective is to get 5% from portfolio every year - 3.5 points from dividends and 1.5 points from capital gains. Prefer higher DGR to higher yield, but need about 3% yield on portfolio.
"...research revealed some surprising results. Over any longer period, say five to ten years, the companies with the lowest dividend yields and the highest consistent dividend growth were the top performers." Divs should be from companies whose long term history is raising divs faster than inflation. Therefore, over time the 1.5 points from stock sales should diminish to $ zero.
The overall portfolio should have 3 buckets of roughly equal proportion:
A. 2 to 3% yielders with high DGR (>10% over at least 10 + years - stocks most often come from Consumer Cyclical, Tech, and Industrial sectors)
B. stocks which have a much higher than average dividend yield, say 4 to 6%,combined with dividend growth at 6 to 8%/yr over 5 + years. Portfolio B stocks are mostly filled with Utilities, Telecommunications, REITs, and Energy stocks.
C. very undervalued stocks which combine a higher than average dividend yield 3 to 4 % with at least a dgr no less than 6%. These stocks don't come from specific sectors because the reasons for undervaluation are company/industry specific headwinds or uncertainties.
% needed from sales equals about 1% of portfolio. Anticipating a 6 to 8%/yr long term increase in portfolio value, not counting divs, I expect portfolio value to increase and therefore provide a necessary cushion to achieving planning objectives.
Stock prices follow earnings in the long term. Therefore, stock prices should increase at roughly the DGR and vice versa. So, primary focus should be on estimated 5 and 1 year EPS growth, followed by 10, 5,3 and 1 year DGR histories.
Be mostly a buyer of high quality dividend stocks, with solid competitive advantages. My holding period is forever, as long as the dividend is at least maintained. But, I do a thorough review every quarter to see if some stocks can be replaced with higher quality without sacrificing yield. Quality in this case means higher: estimated 5 year EPS growth; 10, 5, 3 and 1 year DGR; better Graham; or lower payout ratio. This review causes a turnover of 1 to 2 stocks per quarter.
I Concentrate efforts on stocks which grow earnings and dividends and which provide outstanding total returns over time. For the most part, this means confining choices to the CCC list for security of dividends continuing and growing, and to limit downside swings in portfolio value. Diversify across sectors and geographic locations.
Don’t buy illiquid stocks. Did I say don't buy illiquid stocks.
1. Est 5 year growth > 8 to 10%
2. NY growth > 8 to 10%
3. 5 yr DGR > 8 %
4. 1 yr DGR > 8%
5. D/E 3%), low payout stocks (
I have been occasionally investing, as my personal time and money permit, via long positions over the course of 10 years. I don't work for a brokerage firm, and I'm not a professional trader. My interest has been predominantly within the biotechnology and energy sectors.
I'm a CPA licensed in Maryland. I have Bachelor degrees in both Accounting and Finance.
Stock Twits - http://stocktwits.com/Bio_Bull
Twitter - https://twitter.com/Bio_Bull_SA
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our Editorial Team is comprised of individuals with a strong background in science, medicine and the business of successfully commercializing therapeutics, medical devices, diagnostics and healthcare services. Our ultimate objective is to leverage the knowledge, experience, and relationships of our contributors to introduce our subscribers to profitable long and short investment opportunities in the healthcare sector.
Successfully trading, and investing in emerging growth healthcare companies is a difficult task. Over 90% of drugs never make it out of the clinic. Huge capital requirements along the way result in highly dilutive equity financings often done on the backs of retail investors. At PropThink, we believe that due diligence is the key to success in this industry. We leverage a combined 50 years of experience in science, medicine, legal, regulatory affairs, finance, and operational industry experience to analyze companies at a highly technical level. This detailed analysis and due diligence process defines our editorial strategy and provides our subscribers a high level of confidence in our research. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued.
Visit PropThink.com to see all of our coverage and research, and subscribe to our free newsletter to receive reports, articles, and trading alerts.
Alumni of Indian Institute of Technology, Madras (Bachelors in Chem. Eng) , University of Cincinnati (Masters in Environmental Eng.) and MBA from University of Chicago Booth School of Business (concentrations in Strategy, Economics, Marketing).
Experience working as software consultant, project manager, utility senior engineer, entrepreneur. Areas of expertise include cloud databases, SCADA systems, water treatment, industrial waste water treatment, sensor technology and medical device development,
Currently CEO of a company that makes medical devices.
Our small-cap hedge fund strategy beat the market by 44 percentage points since its inception 18 months ago. Visit our website to learn how you can do the same. Insider Monkey is a finance website that provides free hedge fund and insider trading data. We believe ordinary investors can beat the market by imitating insiders and best hedge fund managers. They have access to better information and experts than ordinary investors do. Take advantage of the SEC filings where hedge funds and insiders disclose their stock transactions.
Here is our team:
Ms. Krishnamsetty is the Editor of Insider Monkey. Prior to creating Insider Monkey with Dr. Dogan, Ms. Krishnamsetty was Associate Producer at Bloomberg Television. Prior to that, Ms. Krishnamsetty was on the afternoon news team at CNBC. Additionally, Ms. Krishnamsetty reported for NPR and worked as a risk management consultant at Marsh & McLennan. Ms. Krishnamsetty has a M.S. in Journalism from Columbia University’s Graduate School of Journalism.
Insider Monkey’s hybrid evaluation system ...More was created in 2003 by Dr. Ian Dogan. Dr. Dogan has a Ph.D. in financial economics with a specialization in insider trading. Dr. Dogan has provided consulting services to institutional investors and hedge funds, and managed a $200+ million fund using a strategy he developed utilizing insider transactions. Dr. Dogan recently authored the insider trading chapter of soon to be published “The Handbook of Investment Anomalies” by Zacks Investment Research. Insider Monkey will serve the outcome of the methodologies developed by Dr. Dogan to ordinary investors who don’t have access to academic quality research and tools to shape their investments.
For your inquiries please contact us at email@example.com
My name is Phil Mause. I am a Senior Advisor with the Pacific Economics Group, focusing on energy, regulatory and valuation issues. I retired from 40 years of law practice earlier this year. I am a yield oriented investor and in the last two years, I have done reasonably well in junk bonds, BDCs, mortgage REITS, and dividend paying blue chip stocks. As an avocation, I dabble in stand up comedy.
Ted Waller is a private investor who bought his first stock at age 13 (GTE) and has over 50 years of investing experience. His focus is on deep value and low risk. Acquiring wealth is a slow incremental process that requires setting goals, adherence to principles, patience, and flexibility.
James A. Kostohryz has accumulated over twenty years of experience investing and trading virtually every asset class across the globe.
Kostohryz started his investment career as an analyst at one of the US's largest asset management firms covering sectors as diverse as emerging markets, banking, energy, construction, real estate, metals and mining. Later, Kostohryz became Chief Global Strategist and Head of International Investments for a major investment bank. Kostohryz currently manages his own investment firm, specializing in proprietary trading and institutional portfolio management advisory.
Born in Mexico, Kostohryz grew up between south Texas and Colombia, has lived and worked in nine different countries, and has traveled extensively in more than 50 others. Kostohryz actively pursues various intellectual interests and is currently writing a book about the impact of culture on economic development. He is a former NCAA and world-class decathlete and has stayed active in a variety of sports.
Kostohryz graduated with honors from both Stanford University and Harvard Law School.
You can receive custom delivery of all of Mr. Kostohryz's published work on Seeking Alpha, The Street, and other media, as well as exclusive material, by following the link below. It is absolutely free:
You may connect with Mr. Kostohryz via the following social networks:
When connecting, be sure to identify yourself as a Seeking Alpha reader.
Contributor is experienced in Bio/Pharma Space. Extensive knowledge across the board both by experience and from the many experts he works with and along side.
Long-term, Big Picture, Valuation and Facts. The keys the most successful use in making money regardless of what day to day challenges and smokescreens appear.
On October 31st, 2014, I retired. Turned in the keys to the company car, gave them my computer and my account lists and joined the ranks of those who "slipped off into the sunset." I never thought in retirement that I would be this busy. It's fun. Time with the grandkids, time to perfect my cooking skills, and time to travel and check off the things on my bucket list. I should have done this a long time ago.
I'm a doctor. For safety and privacy reasons I choose not to share specific details that could identify me and put my family at risk from lunatics in cyberspace. I wish you good health and a prosperous life. Invest wisely, know the facts, and do not forget to help others in this world who may not always have the luxury of a daily meal. God Bless
During the IPO season Francis Gaskins, editor of IPOdesktop.com & director of research for Equities.com, regularly appears on CNBC TV, Bloomberg, thestreet.com & other financial cable channels. On the day of the Visa IPO he appeared on four cable TV financial shows including Bloomberg & CNBC.
Over the past five years he has been quoted over 500 times by such financial media as the Wall Street Journal, Bloomberg, Reuters, Associated Press, USA Today among others. Those quotes are available at IPOdesktop.com.
His varied personal interests include violin playing. For example, he is concertmaster of the Palisades Symphony. He also holds an MBA from Harvard Business School (finance) and an AB from Princeton University (economics).
PRIMARY OBJECTIVE: ... Income Replacement!
Escape velocity is the speed that an object needs to be traveling to break free of the planet's gravitational pull and leave it without further propulsion.
This portfolio is looking for the point where the income being generated can allow the holder of this portfolio to escape the gravitational pull of the market and economic forces of worrying about share prices.
The objective is to generate enough income from assets that the only selling of shares will become an option, not a necessity to survive. Therefore, with enough income being generated, it minimizes the fear of meaningful market corrections as dividends are based on the number of shares owned, not the share price.
Charles (Chuck) C. Carnevale is the creator of F.A.S.T. Graphs™. Chuck is also co-founder of an investment management firm. He has been working in the securities industry since 1970: he has been a partner with a private NYSE member firm, the President of a NASD firm, Vice President and Regional Marketing Director for a major AMEX listed company, and an Associate Vice President and Investment Consulting Services Coordinator for a major NYSE member firm. Prior to forming his own investment firm, he was a partner in a 30-year-old established registered investment advisory in Tampa, Florida. Chuck holds a Bachelor of Science in Economics and Finance from the University of Tampa. Chuck is a sought-after public speaker who is very passionate about spreading the critical message of prudence in money management. Chuck is a Veteran of the Vietnam War and was awarded both the Bronze Star and the Vietnam Honor Medal.
I run the long-term dividend investing website: www.theconservativeincomeinvestor.com
I spend most of my time reading through annual reports looking for a small-cap stock to feature in my monthly edition of "The Conservative Investor Digest." That is where you can find my best work, and that is where I focus my research.
You can become a subscriber here: https://gumroad.com/l/HmqJx
Just an average investor... primarily in American equity and bonds.
(Important Note: My articles, blogs, comments, reference links and messages are not intended to be investment advisements; or to value securities. Examples and considerations are hypothetical and educational. Please consult a financial advisor before making investments in any security. Thank you for reading!)
The writer is a long term value investor and M.Sc graduate in Financial Markets with over 10 years experience. Value can be found in both long and short ideas and uses options to enhance the risk-return profile of investment ideas.
Disclaimer: This article provides opinions and information, but does not contain recommendations or personal investment advice to any specific person for any particular purpose. Do your own research or obtain suitable personal advice.